L-Serine
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00133 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 100 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | familial visceral myopathy | KG + DL |
| 2 | intestinal obstruction | KG + DL |
| 3 | myopathic intestinal pseudoobstruction | KG + DL |
| 4 | unclassified intestinal pseudoobstruction | KG + DL |
| 5 | neuronal intestinal dysplasia, type B | KG + DL |
| 6 | angle-closure glaucoma | KG + DL |
| 7 | intestinal pseudoobstruction, neuronal, chronic idiopathic, X-linked | KG + DL |
| 8 | exercise-induced malignant hyperthermia | KG + DL |
| 9 | traumatic glaucoma | KG + DL |
| 10 | aqueous misdirection | KG + DL |
| 11 | closed-angle glaucoma | KG + DL |
| 12 | neuronal intestinal pseudoobstruction | KG + DL |
| 13 | neovascular glaucoma | KG + DL |
| 14 | glaucomatous atrophy of optic disc | KG + DL |
| 15 | primary hereditary glaucoma | KG + DL |
| 16 | congenital short bowel syndrome 1 | KG + DL |
| 17 | obsolete CFM1 | KG + DL |
| 18 | congenital glaucoma | KG + DL |
| 19 | intestinal motility disease | KG + DL |
| 20 | visceral myopathy | KG + DL |
| 21 | paralytic ileus (disease) | KG + DL |
| 22 | familial periodic paralysis | KG + DL |
| 23 | isolated anophthalmia-microphthalmia syndrome | KG + DL |
| 24 | hypokalemic periodic paralysis | KG + DL |
| 25 | hydrophthalmos | KG + DL |
| 26 | malignant hyperthermia, susceptibility to | KG + DL |
| 27 | xerophthalmia | KG + DL |
| 28 | vitamin deficiency disorder | KG + DL |
| 29 | King-Denborough syndrome | KG + DL |
| 30 | biotin metabolic disease | KG + DL |
| 31 | myopathy, centronuclear | KG + DL |
| 32 | moderate multiminicore disease with hand involvement | KG + DL |
| 33 | central core myopathy | KG + DL |
| 34 | paracetamol poisoning | KG + DL |
| 35 | thyrotoxic periodic paralysis, susceptibility to | KG + DL |
| 36 | mitochondrial oxidative phosphorylation disorder due to nuclear DNA anomalies | KG + DL |
| 37 | congenital multicore myopathy with external ophthalmoplegia | KG + DL |
| 38 | thyrotoxic periodic paralysis | KG + DL |
| 39 | open angle glaucoma | KG + DL |
| 40 | renal tubular acidosis | KG + DL |
| 41 | autosomal dominant neovascular inflammatory vitreoretinopathy | KG + DL |
| 42 | hypoglycemia | KG + DL |
| 43 | pregnancy associated osteoporosis | KG + DL |
| 44 | non-syndromic esophageal malformation | KG + DL |
| 45 | glaucoma 1, open angle | KG + DL |
| 46 | bile duct neoplasm | KG + DL |
| 47 | X-linked centronuclear myopathy | KG + DL |
| 48 | biliary tract disease | KG + DL |
| 49 | succinyl-CoA:3-ketoacid CoA transferase deficiency | KG + DL |
| 50 | periodic paralysis (disease) | KG + DL |
(Showing top 50 of 100 predictions)
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.